Edwards Lifesciences Corporation
EW · NYSE
EW · NYSE
Edwards Lifesciences is a medical-technology company focused on structural-heart therapies and critical-care technologies. It makes money by selling devices and related products used in heart-valve replacement and repair, as well as systems that monitor and support critically ill patients. Its customers include hospitals, health systems, physicians, and other clinical providers. The supplied evidence does not quantify revenue by product or segment. Edwards reported $6.1 billion of fiscal 2025 revenue and $1.1 billion of net income, compared with $5.4 billion of revenue and $4.2 billion of net income in fiscal 2024.
Edwards Lifesciences rose $5.92, or 7.07%, from $83.68 on July 28 to $89.60 on August 4. The move was steady rather than a single-session surge: the stock gained $2.08 Wednesday and $1.16 Thursday, slipped $0.85 Friday, then added $2.75 Monday and $0.78 Tuesday. The supplied evidence identifies no company-specific announcement, earnings release, contract, or analyst action explaining the advance. The only contemporaneous item is a Zacks article asking whether options markets were predicting a spike; its snippet offers no confirmed catalyst. Trading therefore appears to have risen without a documented corporate driver, while the evidence provides no broader market or sector benchmark to explain the move.
Why Edwards Lifesciences (EW) Stock Is Down Today
